All the results for plasma cTnI levels, fibrosis amount and functional echocardiography show that a single dose of the anti-apoptotic TD peptide administered systemically prior to reperfusion constitutes an effective treatment against LV remodeling after myocardial infarction with a persistence of the cardioprotective effect over a 6-month period. The gene discussed is TNNI3; the disease is myocardial infarction.